001package org.hl7.fhir.instance.model.valuesets; 002 003/* 004 Copyright (c) 2011+, HL7, Inc. 005 All rights reserved. 006 007 Redistribution and use in source and binary forms, with or without modification, 008 are permitted provided that the following conditions are met: 009 010 * Redistributions of source code must retain the above copyright notice, this 011 list of conditions and the following disclaimer. 012 * Redistributions in binary form must reproduce the above copyright notice, 013 this list of conditions and the following disclaimer in the documentation 014 and/or other materials provided with the distribution. 015 * Neither the name of HL7 nor the names of its contributors may be used to 016 endorse or promote products derived from this software without specific 017 prior written permission. 018 019 THIS SOFTWARE IS PROVIDED BY THE COPYRIGHT HOLDERS AND CONTRIBUTORS "AS IS" AND 020 ANY EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED 021 WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE ARE DISCLAIMED. 022 IN NO EVENT SHALL THE COPYRIGHT HOLDER OR CONTRIBUTORS BE LIABLE FOR ANY DIRECT, 023 INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, OR CONSEQUENTIAL DAMAGES (INCLUDING, BUT 024 NOT LIMITED TO, PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES; LOSS OF USE, DATA, OR 025 PROFITS; OR BUSINESS INTERRUPTION) HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, 026 WHETHER IN CONTRACT, STRICT LIABILITY, OR TORT (INCLUDING NEGLIGENCE OR OTHERWISE) 027 ARISING IN ANY WAY OUT OF THE USE OF THIS SOFTWARE, EVEN IF ADVISED OF THE 028 POSSIBILITY OF SUCH DAMAGE. 029 030*/ 031 032// Generated on Wed, Nov 11, 2015 10:54-0500 for FHIR v1.0.2 033 034 035public enum V3ObservationInterpretation { 036 037 /** 038 * Codes that specify interpretation of genetic analysis, such as "positive", "negative", "carrier", "responsive", etc. 039 */ 040 _GENETICOBSERVATIONINTERPRETATION, 041 /** 042 * The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder. 043 */ 044 CAR, 045 /** 046 * The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder. 047 048 049 050 Deprecation Comment: 051 This code is currently the same string as the print name for this concept and is inconsistent with the conventions being used for the other codes in the coding system, as it is a full word with initial capitalization, rather than an all upper case mnemonic. The recommendation from OO is to deprecate the code "Carrier" and to add "CAR" as the new active code representation for this concept. 052 */ 053 CARRIER, 054 /** 055 * Interpretations of change of quantity and/or severity. At most one of B or W and one of U or D allowed. 056 */ 057 _OBSERVATIONINTERPRETATIONCHANGE, 058 /** 059 * The current result or observation value has improved compared to the previous result or observation value (the change is significant as defined in the respective test procedure). 060 061 [Note: This can be applied to quantitative or qualitative observations.] 062 */ 063 B, 064 /** 065 * The current result has decreased from the previous result for a quantitative observation (the change is significant as defined in the respective test procedure). 066 */ 067 D, 068 /** 069 * The current result has increased from the previous result for a quantitative observation (the change is significant as defined in the respective test procedure). 070 */ 071 U, 072 /** 073 * The current result or observation value has degraded compared to the previous result or observation value (the change is significant as defined in the respective test procedure). 074 075 [Note: This can be applied to quantitative or qualitative observations.] 076 */ 077 W, 078 /** 079 * Technical exceptions resulting in the inability to provide an interpretation. At most one allowed. Does not imply normality or severity. 080 */ 081 _OBSERVATIONINTERPRETATIONEXCEPTIONS, 082 /** 083 * The result is below the minimum detection limit (the test procedure or equipment is the limiting factor). 084 085 Synonyms: Below analytical limit, low off scale. 086 */ 087 LESS_THAN, 088 /** 089 * The result is above the maximum quantifiable limit (the test procedure or equipment is the limiting factor). 090 091 Synonyms: Above analytical limit, high off scale. 092 */ 093 GREATER_THAN, 094 /** 095 * A valid result cannot be obtained for the specified component / analyte due to the presence of anti-complementary substances in the sample. 096 */ 097 AC, 098 /** 099 * There is insufficient evidence that the species in question is a good target for therapy with the drug. A categorical interpretation is not possible. 100 101 [Note: A MIC with "IE" and/or a comment may be reported (without an accompanying S, I or R-categorization).] 102 */ 103 IE, 104 /** 105 * A result cannot be considered valid for the specified component / analyte or organism due to failure in the quality control testing component. 106 */ 107 QCF, 108 /** 109 * A valid result cannot be obtained for the specified organism or cell line due to the presence of cytotoxic substances in the sample or culture. 110 */ 111 TOX, 112 /** 113 * Interpretation of normality or degree of abnormality (including critical or "alert" level). Concepts in this category are mutually exclusive, i.e., at most one is allowed. 114 */ 115 _OBSERVATIONINTERPRETATIONNORMALITY, 116 /** 117 * The result or observation value is outside the reference range or expected norm (as defined for the respective test procedure). 118 119 [Note: Typically applies to non-numeric results.] 120 */ 121 A, 122 /** 123 * The result or observation value is outside a reference range or expected norm at a level at which immediate action should be considered for patient safety (as defined for the respective test procedure). 124 125 [Note: Typically applies to non-numeric results. Analogous to critical/panic limits for numeric results.] 126 */ 127 AA, 128 /** 129 * The result for a quantitative observation is above a reference level at which immediate action should be considered for patient safety (as defined for the respective test procedure). 130 131 Synonym: Above upper panic limits. 132 */ 133 HH, 134 /** 135 * The result for a quantitative observation is below a reference level at which immediate action should be considered for patient safety (as defined for the respective test procedure). 136 137 Synonym: Below lower panic limits. 138 */ 139 LL, 140 /** 141 * The result for a quantitative observation is above the upper limit of the reference range (as defined for the respective test procedure). 142 143 Synonym: Above high normal 144 */ 145 H, 146 /** 147 * A test result that is significantly higher than the reference (normal) or therapeutic interval, but has not reached the critically high value and might need special attention, as defined by the laboratory or the clinician.[Note: This level is situated between 'H' and 'HH'.] 148 149 150 Deprecation Comment: The code 'H>' is being deprecated in order to align with the use of the code 'HU' for "Very high" in V2 Table 0078 "Interpretation Codes". 151 152 [Note: The use of code 'H>' is non-preferred, as this code is deprecated and on track to be retired; use code 'HU' instead. 153 */ 154 H_, 155 /** 156 * The result for a quantitative observation is below the lower limit of the reference range (as defined for the respective test procedure). 157 158 Synonym: Below low normal 159 */ 160 L, 161 /** 162 * A test result that is significantly lower than the reference (normal) or therapeutic interval, but has not reached the critically low value and might need special attention, as defined by the laboratory or the clinician.[Note: This level is situated between 'L' and 'LL'.] 163 164 165 Deprecation Comment: The code 'L<' is being deprecated in order to align with the use of the code 'LU' for "Very low" in V2 Table 0078 "Interpretation Codes". 166 167 [Note: The use of code 'L<' is non-preferred, as this code is deprecated and on track to be retired; use code 'LU' instead. 168 */ 169 L_, 170 /** 171 * The result or observation value is within the reference range or expected norm (as defined for the respective test procedure). 172 173 [Note: Applies to numeric or non-numeric results.] 174 */ 175 N, 176 /** 177 * Interpretations of anti-microbial susceptibility testing results (microbiology). At most one allowed. 178 */ 179 _OBSERVATIONINTERPRETATIONSUSCEPTIBILITY, 180 /** 181 * Bacterial strain inhibited in vitro by a concentration of an antimicrobial agent that is associated with uncertain therapeutic effect. Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm) 182Projects: ISO 20776-1, ISO 20776-2 183 184 [Note 1: Bacterial strains are categorized as intermediate by applying the appropriate breakpoints in a defined phenotypic test system.] 185 186 [Note 2: This class of susceptibility implies that an infection due to the isolate can be appropriately treated in body sites where the drugs are physiologically concentrated or when a high dosage of drug can be used.] 187 188 [Note 3: This class also indicates a "buffer zone," to prevent small, uncontrolled, technical factors from causing major discrepancies in interpretations.] 189 190 [Note 4: These breakpoints can be altered due to changes in circumstances (e.g. changes in commonly used drug dosages, emergence of new resistance mechanisms).] 191 */ 192 I, 193 /** 194 * The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder. 195 196 197 198 Deprecation Comment: 199 This antimicrobial susceptibility test interpretation concept is recommended by OO to be deprecated as it is no longer recommended for use in susceptibility testing by CLSI (reference CLSI document M100-S22; Vol. 32 No.3; CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Jan 2012). 200 */ 201 MS, 202 /** 203 * A category used for isolates for which only a susceptible interpretive criterion has been designated because of the absence or rare occurrence of resistant strains. Isolates that have MICs above or zone diameters below the value indicated for the susceptible breakpoint should be reported as non-susceptible. 204 205 NOTE 1: An isolate that is interpreted as non-susceptible does not necessarily mean that the isolate has a resistance mechanism. It is possible that isolates with MICs above the susceptible breakpoint that lack resistance mechanisms may be encountered within the wild-type distribution subsequent to the time the susceptible-only breakpoint is set. 206 207 NOTE 2: For strains yielding results in the "nonsusceptible" category, organism identification and antimicrobial susceptibility test results should be confirmed. 208 209 Synonym: decreased susceptibility. 210 */ 211 NS, 212 /** 213 * Bacterial strain inhibited in vitro by a concentration of an antimicrobial agent that is associated with a high likelihood of therapeutic failure. 214Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm) 215Projects: ISO 20776-1, ISO 20776-2 216 217 [Note 1: Bacterial strains are categorized as resistant by applying the appropriate breakpoints in a defined phenotypic test system.] 218 219 [Note 2: This breakpoint can be altered due to changes in circumstances (e.g. changes in commonly used drug dosages, emergence of new resistance mechanisms).] 220 */ 221 R, 222 /** 223 * A category for isolates where the bacteria (e.g. enterococci) are not susceptible in vitro to a combination therapy (e.g. high-level aminoglycoside and cell wall active agent). This is predictive that this combination therapy will not be effective. 224 225 226 Usage Note: Since the use of penicillin or ampicillin alone often results in treatment failure of serious enterococcal or other bacterial infections, combination therapy is usually indicated to enhance bactericidal activity. The synergy between a cell wall active agent (such as penicillin, ampicillin, or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or streptomycin) is best predicted by screening for high-level bacterial resistance to the aminoglycoside. 227 228 229 Open Issue: The print name of the code is very general and the description is very specific to a pair of classes of agents, which may lead to confusion of these concepts in the future should other synergies be found. 230 */ 231 SYNR, 232 /** 233 * Bacterial strain inhibited by in vitro concentration of an antimicrobial agent that is associated with a high likelihood of therapeutic success. 234Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm) 235Synonym (earlier term): Sensitive Projects: ISO 20776-1, ISO 20776-2 236 237 [Note 1: Bacterial strains are categorized as susceptible by applying the appropriate breakpoints in a defined phenotypic system.] 238 239 [Note 2: This breakpoint can be altered due to changes in circumstances (e.g. changes in commonly used drug dosages, emergence of new resistance mechanisms).] 240 */ 241 S, 242 /** 243 * A category that includes isolates with antimicrobial agent minimum inhibitory concentrations (MICs) that approach usually attainable blood and tissue levels and for which response rates may be lower than for susceptible isolates. 244 245 Reference: CLSI document M44-A2 2009 "Method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline - second edition" - page 2. 246 */ 247 SDD, 248 /** 249 * A category for isolates where the bacteria (e.g. enterococci) are susceptible in vitro to a combination therapy (e.g. high-level aminoglycoside and cell wall active agent). This is predictive that this combination therapy will be effective. 250 251 252 Usage Note: Since the use of penicillin or ampicillin alone often results in treatment failure of serious enterococcal or other bacterial infections, combination therapy is usually indicated to enhance bactericidal activity. The synergy between a cell wall active agent (such as penicillin, ampicillin, or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or streptomycin) is best predicted by screening for high-level bacterial resistance to the aminoglycoside. 253 254 255 Open Issue: The print name of the code is very general and the description is very specific to a pair of classes of agents, which may lead to confusion of these concepts in the future should other synergies be found. 256 */ 257 SYNS, 258 /** 259 * The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder. 260 261 262 263 Deprecation Comment: 264 This antimicrobial susceptibility test interpretation concept is recommended by OO to be deprecated as it is no longer recommended for use in susceptibility testing by CLSI (reference CLSI document M100-S22; Vol. 32 No.3; CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Jan 2012). 265 */ 266 VS, 267 /** 268 * The observation/test result is interpreted as being outside the inclusion range for a particular protocol within which the result is being reported. 269 270 271 Example: A positive result on a Hepatitis screening test. 272 Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g. A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. 273These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal "030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. 274Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held. 275 */ 276 EX, 277 /** 278 * The observation/test result is interpreted as being outside the inclusion range for a particular protocol within which the result is being reported. 279 280 281 Example: A positive result on a Hepatitis screening test. 282 Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g. A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal "030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held. 283 */ 284 HX, 285 /** 286 * The numeric observation/test result is interpreted as being below the low threshold value for a particular protocol within which the result is being reported. 287 288 Example: A Total White Blood Cell Count falling below a protocol-defined threshold value of 3000/mm^3 289 Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g. A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal "030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held. 290 */ 291 LX, 292 /** 293 * Interpretations of the presence or absence of a component / analyte or organism in a test or of a sign in a clinical observation. In keeping with laboratory data processing practice, these concepts provide a categorical interpretation of the "meaning" of the quantitative value for the same observation. 294 */ 295 OBSERVATIONINTERPRETATIONDETECTION, 296 /** 297 * The specified component / analyte, organism or clinical sign could neither be declared positive / negative or detected / not detected by the performed test or procedure. 298 */ 299 IND, 300 /** 301 * An absence finding of the specified component / analyte, organism or clinical sign based on the established threshold of the performed test or procedure. 302 303 [Note: Negative does not necessarily imply the complete absence of the specified item.] 304 */ 305 NEG, 306 /** 307 * The presence of the specified component / analyte, organism or clinical sign could not be determined within the limit of detection of the performed test or procedure. 308 */ 309 ND, 310 /** 311 * A presence finding of the specified component / analyte, organism or clinical sign based on the established threshold of the performed test or procedure. 312 */ 313 POS, 314 /** 315 * The measurement of the specified component / analyte, organism or clinical sign above the limit of detection of the performed test or procedure. 316 */ 317 DET, 318 /** 319 * Interpretation of the observed result taking into account additional information (contraindicators) about the patient's situation. Concepts in this category are mutually exclusive, i.e., at most one is allowed. 320 */ 321 OBSERVATIONINTERPRETATIONEXPECTATION, 322 /** 323 * This result has been evaluated in light of known contraindicators. Once those contraindicators have been taken into account the result is determined to be "Expected" (e.g. presence of drugs in a patient that is taking prescription medication for pain management). 324 */ 325 EXP, 326 /** 327 * This result has been evaluated in light of known contraindicators. Once those contraindicators have been taken into account the result is determined to be "Unexpected" (e.g. presence of non-prescribed drugs in a patient that is taking prescription medication for pain management). 328 */ 329 UNE, 330 /** 331 * Interpretations of the presence and level of reactivity of the specified component / analyte with the reagent in the performed laboratory test. 332 */ 333 REACTIVITYOBSERVATIONINTERPRETATION, 334 /** 335 * An absence finding used to indicate that the specified component / analyte did not react measurably with the reagent. 336 */ 337 NR, 338 /** 339 * A presence finding used to indicate that the specified component / analyte reacted with the reagent above the reliably measurable limit of the performed test. 340 */ 341 RR, 342 /** 343 * A weighted presence finding used to indicate that the specified component / analyte reacted with the reagent, but below the reliably measurable limit of the performed test. 344 */ 345 WR, 346 /** 347 * added to help the parsers 348 */ 349 NULL; 350 public static V3ObservationInterpretation fromCode(String codeString) throws Exception { 351 if (codeString == null || "".equals(codeString)) 352 return null; 353 if ("_GeneticObservationInterpretation".equals(codeString)) 354 return _GENETICOBSERVATIONINTERPRETATION; 355 if ("CAR".equals(codeString)) 356 return CAR; 357 if ("Carrier".equals(codeString)) 358 return CARRIER; 359 if ("_ObservationInterpretationChange".equals(codeString)) 360 return _OBSERVATIONINTERPRETATIONCHANGE; 361 if ("B".equals(codeString)) 362 return B; 363 if ("D".equals(codeString)) 364 return D; 365 if ("U".equals(codeString)) 366 return U; 367 if ("W".equals(codeString)) 368 return W; 369 if ("_ObservationInterpretationExceptions".equals(codeString)) 370 return _OBSERVATIONINTERPRETATIONEXCEPTIONS; 371 if ("<".equals(codeString)) 372 return LESS_THAN; 373 if (">".equals(codeString)) 374 return GREATER_THAN; 375 if ("AC".equals(codeString)) 376 return AC; 377 if ("IE".equals(codeString)) 378 return IE; 379 if ("QCF".equals(codeString)) 380 return QCF; 381 if ("TOX".equals(codeString)) 382 return TOX; 383 if ("_ObservationInterpretationNormality".equals(codeString)) 384 return _OBSERVATIONINTERPRETATIONNORMALITY; 385 if ("A".equals(codeString)) 386 return A; 387 if ("AA".equals(codeString)) 388 return AA; 389 if ("HH".equals(codeString)) 390 return HH; 391 if ("LL".equals(codeString)) 392 return LL; 393 if ("H".equals(codeString)) 394 return H; 395 if ("H>".equals(codeString)) 396 return H_; 397 if ("L".equals(codeString)) 398 return L; 399 if ("L<".equals(codeString)) 400 return L_; 401 if ("N".equals(codeString)) 402 return N; 403 if ("_ObservationInterpretationSusceptibility".equals(codeString)) 404 return _OBSERVATIONINTERPRETATIONSUSCEPTIBILITY; 405 if ("I".equals(codeString)) 406 return I; 407 if ("MS".equals(codeString)) 408 return MS; 409 if ("NS".equals(codeString)) 410 return NS; 411 if ("R".equals(codeString)) 412 return R; 413 if ("SYN-R".equals(codeString)) 414 return SYNR; 415 if ("S".equals(codeString)) 416 return S; 417 if ("SDD".equals(codeString)) 418 return SDD; 419 if ("SYN-S".equals(codeString)) 420 return SYNS; 421 if ("VS".equals(codeString)) 422 return VS; 423 if ("EX".equals(codeString)) 424 return EX; 425 if ("HX".equals(codeString)) 426 return HX; 427 if ("LX".equals(codeString)) 428 return LX; 429 if ("ObservationInterpretationDetection".equals(codeString)) 430 return OBSERVATIONINTERPRETATIONDETECTION; 431 if ("IND".equals(codeString)) 432 return IND; 433 if ("NEG".equals(codeString)) 434 return NEG; 435 if ("ND".equals(codeString)) 436 return ND; 437 if ("POS".equals(codeString)) 438 return POS; 439 if ("DET".equals(codeString)) 440 return DET; 441 if ("ObservationInterpretationExpectation".equals(codeString)) 442 return OBSERVATIONINTERPRETATIONEXPECTATION; 443 if ("EXP".equals(codeString)) 444 return EXP; 445 if ("UNE".equals(codeString)) 446 return UNE; 447 if ("ReactivityObservationInterpretation".equals(codeString)) 448 return REACTIVITYOBSERVATIONINTERPRETATION; 449 if ("NR".equals(codeString)) 450 return NR; 451 if ("RR".equals(codeString)) 452 return RR; 453 if ("WR".equals(codeString)) 454 return WR; 455 throw new Exception("Unknown V3ObservationInterpretation code '"+codeString+"'"); 456 } 457 public String toCode() { 458 switch (this) { 459 case _GENETICOBSERVATIONINTERPRETATION: return "_GeneticObservationInterpretation"; 460 case CAR: return "CAR"; 461 case CARRIER: return "Carrier"; 462 case _OBSERVATIONINTERPRETATIONCHANGE: return "_ObservationInterpretationChange"; 463 case B: return "B"; 464 case D: return "D"; 465 case U: return "U"; 466 case W: return "W"; 467 case _OBSERVATIONINTERPRETATIONEXCEPTIONS: return "_ObservationInterpretationExceptions"; 468 case LESS_THAN: return "<"; 469 case GREATER_THAN: return ">"; 470 case AC: return "AC"; 471 case IE: return "IE"; 472 case QCF: return "QCF"; 473 case TOX: return "TOX"; 474 case _OBSERVATIONINTERPRETATIONNORMALITY: return "_ObservationInterpretationNormality"; 475 case A: return "A"; 476 case AA: return "AA"; 477 case HH: return "HH"; 478 case LL: return "LL"; 479 case H: return "H"; 480 case H_: return "H>"; 481 case L: return "L"; 482 case L_: return "L<"; 483 case N: return "N"; 484 case _OBSERVATIONINTERPRETATIONSUSCEPTIBILITY: return "_ObservationInterpretationSusceptibility"; 485 case I: return "I"; 486 case MS: return "MS"; 487 case NS: return "NS"; 488 case R: return "R"; 489 case SYNR: return "SYN-R"; 490 case S: return "S"; 491 case SDD: return "SDD"; 492 case SYNS: return "SYN-S"; 493 case VS: return "VS"; 494 case EX: return "EX"; 495 case HX: return "HX"; 496 case LX: return "LX"; 497 case OBSERVATIONINTERPRETATIONDETECTION: return "ObservationInterpretationDetection"; 498 case IND: return "IND"; 499 case NEG: return "NEG"; 500 case ND: return "ND"; 501 case POS: return "POS"; 502 case DET: return "DET"; 503 case OBSERVATIONINTERPRETATIONEXPECTATION: return "ObservationInterpretationExpectation"; 504 case EXP: return "EXP"; 505 case UNE: return "UNE"; 506 case REACTIVITYOBSERVATIONINTERPRETATION: return "ReactivityObservationInterpretation"; 507 case NR: return "NR"; 508 case RR: return "RR"; 509 case WR: return "WR"; 510 default: return "?"; 511 } 512 } 513 public String getSystem() { 514 return "http://hl7.org/fhir/v3/ObservationInterpretation"; 515 } 516 public String getDefinition() { 517 switch (this) { 518 case _GENETICOBSERVATIONINTERPRETATION: return "Codes that specify interpretation of genetic analysis, such as \"positive\", \"negative\", \"carrier\", \"responsive\", etc."; 519 case CAR: return "The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder."; 520 case CARRIER: return "The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder.\r\n\n \n \n Deprecation Comment: \n This code is currently the same string as the print name for this concept and is inconsistent with the conventions being used for the other codes in the coding system, as it is a full word with initial capitalization, rather than an all upper case mnemonic. The recommendation from OO is to deprecate the code \"Carrier\" and to add \"CAR\" as the new active code representation for this concept."; 521 case _OBSERVATIONINTERPRETATIONCHANGE: return "Interpretations of change of quantity and/or severity. At most one of B or W and one of U or D allowed."; 522 case B: return "The current result or observation value has improved compared to the previous result or observation value (the change is significant as defined in the respective test procedure).\r\n\n [Note: This can be applied to quantitative or qualitative observations.]"; 523 case D: return "The current result has decreased from the previous result for a quantitative observation (the change is significant as defined in the respective test procedure)."; 524 case U: return "The current result has increased from the previous result for a quantitative observation (the change is significant as defined in the respective test procedure)."; 525 case W: return "The current result or observation value has degraded compared to the previous result or observation value (the change is significant as defined in the respective test procedure).\r\n\n [Note: This can be applied to quantitative or qualitative observations.]"; 526 case _OBSERVATIONINTERPRETATIONEXCEPTIONS: return "Technical exceptions resulting in the inability to provide an interpretation. At most one allowed. Does not imply normality or severity."; 527 case LESS_THAN: return "The result is below the minimum detection limit (the test procedure or equipment is the limiting factor).\r\n\n Synonyms: Below analytical limit, low off scale."; 528 case GREATER_THAN: return "The result is above the maximum quantifiable limit (the test procedure or equipment is the limiting factor).\r\n\n Synonyms: Above analytical limit, high off scale."; 529 case AC: return "A valid result cannot be obtained for the specified component / analyte due to the presence of anti-complementary substances in the sample."; 530 case IE: return "There is insufficient evidence that the species in question is a good target for therapy with the drug. A categorical interpretation is not possible.\r\n\n [Note: A MIC with \"IE\" and/or a comment may be reported (without an accompanying S, I or R-categorization).]"; 531 case QCF: return "A result cannot be considered valid for the specified component / analyte or organism due to failure in the quality control testing component."; 532 case TOX: return "A valid result cannot be obtained for the specified organism or cell line due to the presence of cytotoxic substances in the sample or culture."; 533 case _OBSERVATIONINTERPRETATIONNORMALITY: return "Interpretation of normality or degree of abnormality (including critical or \"alert\" level). Concepts in this category are mutually exclusive, i.e., at most one is allowed."; 534 case A: return "The result or observation value is outside the reference range or expected norm (as defined for the respective test procedure).\r\n\n [Note: Typically applies to non-numeric results.]"; 535 case AA: return "The result or observation value is outside a reference range or expected norm at a level at which immediate action should be considered for patient safety (as defined for the respective test procedure).\r\n\n [Note: Typically applies to non-numeric results. Analogous to critical/panic limits for numeric results.]"; 536 case HH: return "The result for a quantitative observation is above a reference level at which immediate action should be considered for patient safety (as defined for the respective test procedure).\r\n\n Synonym: Above upper panic limits."; 537 case LL: return "The result for a quantitative observation is below a reference level at which immediate action should be considered for patient safety (as defined for the respective test procedure).\r\n\n Synonym: Below lower panic limits."; 538 case H: return "The result for a quantitative observation is above the upper limit of the reference range (as defined for the respective test procedure).\r\n\n Synonym: Above high normal"; 539 case H_: return "A test result that is significantly higher than the reference (normal) or therapeutic interval, but has not reached the critically high value and might need special attention, as defined by the laboratory or the clinician.[Note: This level is situated between 'H' and 'HH'.]\r\n\n \n Deprecation Comment: The code 'H>' is being deprecated in order to align with the use of the code 'HU' for \"Very high\" in V2 Table 0078 \"Interpretation Codes\".\r\n\n [Note: The use of code 'H>' is non-preferred, as this code is deprecated and on track to be retired; use code 'HU' instead."; 540 case L: return "The result for a quantitative observation is below the lower limit of the reference range (as defined for the respective test procedure).\r\n\n Synonym: Below low normal"; 541 case L_: return "A test result that is significantly lower than the reference (normal) or therapeutic interval, but has not reached the critically low value and might need special attention, as defined by the laboratory or the clinician.[Note: This level is situated between 'L' and 'LL'.]\r\n\n \n Deprecation Comment: The code 'L<' is being deprecated in order to align with the use of the code 'LU' for \"Very low\" in V2 Table 0078 \"Interpretation Codes\".\r\n\n [Note: The use of code 'L<' is non-preferred, as this code is deprecated and on track to be retired; use code 'LU' instead."; 542 case N: return "The result or observation value is within the reference range or expected norm (as defined for the respective test procedure).\r\n\n [Note: Applies to numeric or non-numeric results.]"; 543 case _OBSERVATIONINTERPRETATIONSUSCEPTIBILITY: return "Interpretations of anti-microbial susceptibility testing results (microbiology). At most one allowed."; 544 case I: return "Bacterial strain inhibited in vitro by a concentration of an antimicrobial agent that is associated with uncertain therapeutic effect. Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm)\nProjects: ISO 20776-1, ISO 20776-2\r\n\n [Note 1: Bacterial strains are categorized as intermediate by applying the appropriate breakpoints in a defined phenotypic test system.]\r\n\n [Note 2: This class of susceptibility implies that an infection due to the isolate can be appropriately treated in body sites where the drugs are physiologically concentrated or when a high dosage of drug can be used.]\r\n\n [Note 3: This class also indicates a \"buffer zone,\" to prevent small, uncontrolled, technical factors from causing major discrepancies in interpretations.]\r\n\n [Note 4: These breakpoints can be altered due to changes in circumstances (e.g. changes in commonly used drug dosages, emergence of new resistance mechanisms).]"; 545 case MS: return "The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder.\r\n\n \n \n Deprecation Comment: \n This antimicrobial susceptibility test interpretation concept is recommended by OO to be deprecated as it is no longer recommended for use in susceptibility testing by CLSI (reference CLSI document M100-S22; Vol. 32 No.3; CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Jan 2012)."; 546 case NS: return "A category used for isolates for which only a susceptible interpretive criterion has been designated because of the absence or rare occurrence of resistant strains. Isolates that have MICs above or zone diameters below the value indicated for the susceptible breakpoint should be reported as non-susceptible.\r\n\n NOTE 1: An isolate that is interpreted as non-susceptible does not necessarily mean that the isolate has a resistance mechanism. It is possible that isolates with MICs above the susceptible breakpoint that lack resistance mechanisms may be encountered within the wild-type distribution subsequent to the time the susceptible-only breakpoint is set. \r\n\n NOTE 2: For strains yielding results in the \"nonsusceptible\" category, organism identification and antimicrobial susceptibility test results should be confirmed.\r\n\n Synonym: decreased susceptibility."; 547 case R: return "Bacterial strain inhibited in vitro by a concentration of an antimicrobial agent that is associated with a high likelihood of therapeutic failure.\nReference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm) \nProjects: ISO 20776-1, ISO 20776-2\r\n\n [Note 1: Bacterial strains are categorized as resistant by applying the appropriate breakpoints in a defined phenotypic test system.]\r\n\n [Note 2: This breakpoint can be altered due to changes in circumstances (e.g. changes in commonly used drug dosages, emergence of new resistance mechanisms).]"; 548 case SYNR: return "A category for isolates where the bacteria (e.g. enterococci) are not susceptible in vitro to a combination therapy (e.g. high-level aminoglycoside and cell wall active agent). This is predictive that this combination therapy will not be effective. \r\n\n \n Usage Note: Since the use of penicillin or ampicillin alone often results in treatment failure of serious enterococcal or other bacterial infections, combination therapy is usually indicated to enhance bactericidal activity. The synergy between a cell wall active agent (such as penicillin, ampicillin, or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or streptomycin) is best predicted by screening for high-level bacterial resistance to the aminoglycoside.\r\n\n \n Open Issue: The print name of the code is very general and the description is very specific to a pair of classes of agents, which may lead to confusion of these concepts in the future should other synergies be found."; 549 case S: return "Bacterial strain inhibited by in vitro concentration of an antimicrobial agent that is associated with a high likelihood of therapeutic success.\nReference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm)\nSynonym (earlier term): Sensitive Projects: ISO 20776-1, ISO 20776-2\r\n\n [Note 1: Bacterial strains are categorized as susceptible by applying the appropriate breakpoints in a defined phenotypic system.]\r\n\n [Note 2: This breakpoint can be altered due to changes in circumstances (e.g. changes in commonly used drug dosages, emergence of new resistance mechanisms).]"; 550 case SDD: return "A category that includes isolates with antimicrobial agent minimum inhibitory concentrations (MICs) that approach usually attainable blood and tissue levels and for which response rates may be lower than for susceptible isolates.\r\n\n Reference: CLSI document M44-A2 2009 \"Method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline - second edition\" - page 2."; 551 case SYNS: return "A category for isolates where the bacteria (e.g. enterococci) are susceptible in vitro to a combination therapy (e.g. high-level aminoglycoside and cell wall active agent). This is predictive that this combination therapy will be effective. \r\n\n \n Usage Note: Since the use of penicillin or ampicillin alone often results in treatment failure of serious enterococcal or other bacterial infections, combination therapy is usually indicated to enhance bactericidal activity. The synergy between a cell wall active agent (such as penicillin, ampicillin, or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or streptomycin) is best predicted by screening for high-level bacterial resistance to the aminoglycoside.\r\n\n \n Open Issue: The print name of the code is very general and the description is very specific to a pair of classes of agents, which may lead to confusion of these concepts in the future should other synergies be found."; 552 case VS: return "The patient is considered as carrier based on the testing results. A carrier is an individual who carries an altered form of a gene which can lead to having a child or offspring in future generations with a genetic disorder.\r\n\n \n \n Deprecation Comment: \n This antimicrobial susceptibility test interpretation concept is recommended by OO to be deprecated as it is no longer recommended for use in susceptibility testing by CLSI (reference CLSI document M100-S22; Vol. 32 No.3; CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Jan 2012)."; 553 case EX: return "The observation/test result is interpreted as being outside the inclusion range for a particular protocol within which the result is being reported.\n\r\n\n Example: A positive result on a Hepatitis screening test.\n Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g. A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects.\nThese concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal \"030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455\". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes.\nMembers of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held."; 554 case HX: return "The observation/test result is interpreted as being outside the inclusion range for a particular protocol within which the result is being reported.\n\r\n\n Example: A positive result on a Hepatitis screening test.\n Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g. A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal \"030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455\". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held."; 555 case LX: return "The numeric observation/test result is interpreted as being below the low threshold value for a particular protocol within which the result is being reported.\r\n\n Example: A Total White Blood Cell Count falling below a protocol-defined threshold value of 3000/mm^3\n Open Issue: EX, HX, LX: These three concepts do not seem to meet a clear need in the vocabulary, and their use in observation interpretation appears likely to be covered by other existing concepts (e.g. A, H, L). The only apparent significant difference is their reference to use in protocols for exclusion of study subjects. These concepts/codes were proposed by RCRIM for use in the CTLaboratory message. They were submitted and approved in the November 2005 Harmonization cycle in proposal \"030103C_VOCAB_RCRIM_l_quade_RCRIM Obs Interp_20051028154455\". However, this proposal was not fully implemented in the vocabulary. The proposal recommended creation of the x_ClinicalResearchExclusion domain in ObservationInterpretation with a value set including those three concepts/codes, but there is no subdomain of that name or equivalent with a binding to either of the value sets that contain these concepts/codes. Members of the OO WG have recently attempted to contact members of RCRIM regarding these concepts, both by email and at the recent WGM in Atlanta, without response. It is felt by OO that the best course of action to take at this time is to add this comprehensive Open Issue rather than deprecate these three concepts at this time, until further discussion is held."; 556 case OBSERVATIONINTERPRETATIONDETECTION: return "Interpretations of the presence or absence of a component / analyte or organism in a test or of a sign in a clinical observation. In keeping with laboratory data processing practice, these concepts provide a categorical interpretation of the \"meaning\" of the quantitative value for the same observation."; 557 case IND: return "The specified component / analyte, organism or clinical sign could neither be declared positive / negative or detected / not detected by the performed test or procedure."; 558 case NEG: return "An absence finding of the specified component / analyte, organism or clinical sign based on the established threshold of the performed test or procedure.\r\n\n [Note: Negative does not necessarily imply the complete absence of the specified item.]"; 559 case ND: return "The presence of the specified component / analyte, organism or clinical sign could not be determined within the limit of detection of the performed test or procedure."; 560 case POS: return "A presence finding of the specified component / analyte, organism or clinical sign based on the established threshold of the performed test or procedure."; 561 case DET: return "The measurement of the specified component / analyte, organism or clinical sign above the limit of detection of the performed test or procedure."; 562 case OBSERVATIONINTERPRETATIONEXPECTATION: return "Interpretation of the observed result taking into account additional information (contraindicators) about the patient's situation. Concepts in this category are mutually exclusive, i.e., at most one is allowed."; 563 case EXP: return "This result has been evaluated in light of known contraindicators. Once those contraindicators have been taken into account the result is determined to be \"Expected\" (e.g. presence of drugs in a patient that is taking prescription medication for pain management)."; 564 case UNE: return "This result has been evaluated in light of known contraindicators. Once those contraindicators have been taken into account the result is determined to be \"Unexpected\" (e.g. presence of non-prescribed drugs in a patient that is taking prescription medication for pain management)."; 565 case REACTIVITYOBSERVATIONINTERPRETATION: return "Interpretations of the presence and level of reactivity of the specified component / analyte with the reagent in the performed laboratory test."; 566 case NR: return "An absence finding used to indicate that the specified component / analyte did not react measurably with the reagent."; 567 case RR: return "A presence finding used to indicate that the specified component / analyte reacted with the reagent above the reliably measurable limit of the performed test."; 568 case WR: return "A weighted presence finding used to indicate that the specified component / analyte reacted with the reagent, but below the reliably measurable limit of the performed test."; 569 default: return "?"; 570 } 571 } 572 public String getDisplay() { 573 switch (this) { 574 case _GENETICOBSERVATIONINTERPRETATION: return "GeneticObservationInterpretation"; 575 case CAR: return "Carrier"; 576 case CARRIER: return "Carrier"; 577 case _OBSERVATIONINTERPRETATIONCHANGE: return "ObservationInterpretationChange"; 578 case B: return "Better"; 579 case D: return "Significant change down"; 580 case U: return "Significant change up"; 581 case W: return "Worse"; 582 case _OBSERVATIONINTERPRETATIONEXCEPTIONS: return "ObservationInterpretationExceptions"; 583 case LESS_THAN: return "Off scale low"; 584 case GREATER_THAN: return "Off scale high"; 585 case AC: return "Anti-complementary substances present"; 586 case IE: return "Insufficient evidence"; 587 case QCF: return "Quality control failure"; 588 case TOX: return "Cytotoxic substance present"; 589 case _OBSERVATIONINTERPRETATIONNORMALITY: return "ObservationInterpretationNormality"; 590 case A: return "Abnormal"; 591 case AA: return "Critical abnormal"; 592 case HH: return "Critical high"; 593 case LL: return "Critical low"; 594 case H: return "High"; 595 case H_: return "Significantly high"; 596 case L: return "Low"; 597 case L_: return "Significantly low"; 598 case N: return "Normal"; 599 case _OBSERVATIONINTERPRETATIONSUSCEPTIBILITY: return "ObservationInterpretationSusceptibility"; 600 case I: return "Intermediate"; 601 case MS: return "moderately susceptible"; 602 case NS: return "Non-susceptible"; 603 case R: return "Resistant"; 604 case SYNR: return "Synergy - resistant"; 605 case S: return "Susceptible"; 606 case SDD: return "Susceptible-dose dependent"; 607 case SYNS: return "Synergy - susceptible"; 608 case VS: return "very susceptible"; 609 case EX: return "outside threshold"; 610 case HX: return "above high threshold"; 611 case LX: return "below low threshold"; 612 case OBSERVATIONINTERPRETATIONDETECTION: return "ObservationInterpretationDetection"; 613 case IND: return "Indeterminate"; 614 case NEG: return "Negative"; 615 case ND: return "Not detected"; 616 case POS: return "Positive"; 617 case DET: return "Detected"; 618 case OBSERVATIONINTERPRETATIONEXPECTATION: return "ObservationInterpretationExpectation"; 619 case EXP: return "Expected"; 620 case UNE: return "Unexpected"; 621 case REACTIVITYOBSERVATIONINTERPRETATION: return "ReactivityObservationInterpretation"; 622 case NR: return "Non-reactive"; 623 case RR: return "Reactive"; 624 case WR: return "Weakly reactive"; 625 default: return "?"; 626 } 627 } 628 629 630} 631